| Literature DB >> 28901817 |
Ohad S Bentur1, Ronit Gurion2,3, Anat Gafter-Gvili2,3,4, Moshe Gatt5,6, Lev Shvidel6,7, Netanel A Horowitz8, Ron Ram1,3, Yair Herishanu1,3, Nadav Sarid1, Ora Paltiel5,6, Chezi Ganzel6,9, Natalia Kreiniz10, Najib Dally11, Odit Gutwein3,12, Pia Raanani2,3, Irit Avivi1,3, Chava Perry1,3.
Abstract
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography-computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60-80% and 80-93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of "genuine" stage I disease.Entities:
Keywords: Follicular lymphoma; immunotherapy; positron emission tomography; radiotherapy; rituximab
Mesh：
Substances：
Year: 2017 PMID： 28901817 DOI： 10.1080/10428194.2017.1375102
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022